Laboratory Effects of Hirudotherapy

Documented Parameter Changes in Published Clinical Studies

Last Updated: March 1, 2026Reviewed by: Andrei Dokukin, MDGRADE: Moderate

This reference summarizes laboratory parameters documented in published clinical studies. Monitoring recommendations are for educational purposes. All clinical decisions should be made by the treating physician based on individual patient assessment.

Objective assessment of clinical improvement during hirudotherapy (HT) requires monitoring of laboratory and instrumental parameters beyond coagulation studies and circulatory function. Published data document significant effects on lipid metabolism, hematologic indices, protein and bilirubin metabolism, hepatic detoxification, and biophysical monitoring modalities. Understanding these changes is essential for safe practice, documentation of therapeutic response, and evidence-based decision-making about treatment continuation or modification.

Lipid Metabolism

Disorders of lipid metabolism are among the most prevalent conditions associated with atherosclerotic cardiovascular disease. The SGS of medicinal leeches contains lipases and cholesterol esterases with lipolytic activity (Baskova et al., 1983–1989), providing a mechanistic basis for the observed lipid-modifying effects. As early as 1909, Weil and Boye proposed that leech use could prevent sclerosis development.

Isakhanian (1991) — Single Application, 5 Leeches to Hepatic Region (n=20)

Parameter	Baseline (M ± m)	After ML Detachment	P
Total lipids (g/L)	6.77 ± 0.29	6.03 ± 0.29	>0.1
Cholesterol (mmol/L)	4.69 ± 0.26	3.99 ± 0.14	<0.05
Triglycerides (mmol/L)	1.29 ± 0.05	0.89 ± 0.14	<0.05
Beta-lipoproteins (g/L)	4.12 ± 0.20	3.69 ± 0.10	>0.1

Population: CAD, chronic pulmonary disease, rheumatic heart disease. Statistically significant reductions in cholesterol and triglycerides achieved after a single application session.

Published Lipid Studies

Study	Year	Population	n	Key Finding
Isakhanian et al.	1989–91	CAD, chronic pulmonary, rheumatic	20	TC ↓ (p<0.05); TG ↓ (p<0.05)
Kovalenko et al.	1998	CAD	43	90-day: TC ↓ (p<0.05), TG ↓ (p<0.05), LDL ↓ (p<0.01), HDL ↑ (p<0.05)
Zadorova	1998	CAD + hypertension	NR	TC returned to reference range 57%; LDL ↓ 52%; atherogenic index ↓ 50%
Sidorov, Gilyova et al.	1998	Arterial hypertension	NR	TC and TG decreased significantly
Seselkina et al.	1998	Acute stroke	NR	TC and TG decreased significantly
Dong, Chen, Tang	1995	Primary glomerulonephritis	31	Significant TC and TG improvement; proteinuria reduction
Deryabin et al.	1999	MI + hypertension	NR	Tendency toward lower TC and higher HDL
Azarov et al.	1999	CAD	NR	Reductions in TC, LDL, and atherogenic coefficient
Fedina, Korotygina	2001	HD (HT + craniocorporal therapy)	NR	Lipoprotein levels reduced in 95%; TC returned to reference range in nearly all

Clinical Interpretation

The convergent finding across nine independent studies is that HT significantly reduces blood cholesterol and triglyceride concentrations. Reductions in LDL, the atherogenic index, and increases in HDL-C are documented — particularly in the Kovalenko study with 90-day follow-up (n=43), suggesting sustained metabolic effects beyond the acute treatment period. The lipid-modifying mechanism is attributable to SGS lipases and cholesterol esterases (see atherosclerosis mechanisms page), with potential additional contribution from improved hepatic function secondary to hepatic venous decompression.

Note: Available sample sizes and study designs are insufficient to establish a pronounced independent anti-atherosclerotic effect. These are Tier C (observational) findings requiring prospective controlled confirmation.

Recommended Lipid Panel

Parameter	When to Obtain	Normal Range	Clinical Relevance
Total cholesterol	Baseline, 4 weeks, 12 weeks	<200 mg/dL (5.2 mmol/L)	Primary screen
LDL-C	Baseline, 4 weeks, 12 weeks	<100 mg/dL in CAD patients	Atherogenic risk
HDL-C	Baseline, 4 weeks, 12 weeks	>40 mg/dL (men), >50 mg/dL (women)	Protective marker
Triglycerides	Baseline, 4 weeks, 12 weeks	<150 mg/dL (1.7 mmol/L)	Metabolic risk
Non-HDL-C	Baseline, 12 weeks	<130 mg/dL in CAD patients	Composite atherogenic marker

Hemoglobin & Blood Cell Parameters

HT is accompanied by prolonged post-detachment bleeding, raising the theoretical concern of iatrogenic anemia. The clinical evidence indicates that significant anemia is uncommon in standard therapeutic protocols but requires monitoring in intensive surgical settings.

Published Hematologic Data

Study	Year	Population	Key Finding
Eldor et al.	1998	Post-phlebitic syndrome	No Hgb decline even with >20 sessions
Zhivoglad, Nikonova	1997	Mixed	Hgb declined ~1% after HT; values remained within normal range
Rao et al.	1985	Reconstructive surgery (daily ML × several days)	Hgb fell 1–2% over 5-day course; 50% of children required transfusion
Iafolla	1995	Neonate (penile congestion post-bladder exstrophy)	Full tissue recovery but transfusion of packed RBCs required
Startseva et al.	2001	Endometriosis (intravaginal ML)	Significant RBC/Hgb decrease after 1–2 sessions; recovered by end of course. Platelet ↓ (p<0.05), normalized before next course
Lukina, Korletyanu	1999	Healthy volunteers + rat model	Humans: no red cell changes; ESR significantly slowed (p<0.05). Segmented neutrophils ↑ (p<0.05), lymphocytes ↓ (p<0.05). No eosinophilia
Isakhanian	1991	MI (n=12)	Single ML application did NOT alter platelet count: 259.16 ± 8.46/µL (unchanged)
Seselkina et al.	1998	Acute ischemic stroke	Tendency toward declining Hgb; no significant leukocyte differential changes
Vedeneeva, Medvedeva	2000	Acute thyroiditis (n=8)	Marked ESR reduction attributable to HT

Leukocyte Dynamics

Dimitri and Somnes (1931) described a characteristic leukocyte sequence:

16–18 hours: Leukocytosis (stress response)
18–24 hours: Leukopenia due to lymphocyte increase
24–30 hours: Return to baseline

This transient pattern is consistent with a stress-response leukogram followed by compensatory redistribution. It is attributed to autonomic nervous system activation and reticuloendothelial stimulation — not a pathological process.

Eosinophilia Does Not Develop

Lukina and Korletyanu (1999) confirmed that eosinophilia does not develop in either humans or animal models during HT. This is clinically reassuring: the absence of eosinophilia argues against an IgE-mediated allergic mechanism of HT-induced leukocyte changes. Leukocyte shifts should be interpreted as physiological response to the therapeutic stimulus rather than adverse allergic sensitization.

Species-Specific Differences

In humans: relative increase in segmented neutrophils (p<0.05) with relative decrease in lymphocytes (p<0.05). In the rat model: the reverse pattern was observed. This species-specific difference suggests the leukocyte response is mediated through the autonomic nervous system and reticuloendothelial apparatus rather than through direct SGS effects on hematopoiesis.

ESR Reduction

ESR was significantly slowed (p<0.05) in both Lukina/Korletyanu (1999) and Vedeneeva/Medvedeva (2000) studies. ESR reduction may represent a secondary benefit mediated by cholesterol reduction — elevated cholesterol increases erythrocyte aggregation and ESR, while the lipolytic action of SGS reduces this effect.

Microsurgical Exception: Daily intensive surgical use (3–6 leeches every 4 hours for up to 5 days) produces significant cumulative blood loss. In microsurgical flap salvage, 49.75% of patients require transfusion. This is an expected consequence of the intensive protocol, not a complication of leech therapy per se. Daily CBC monitoring is mandatory in these settings.

Clinical Implications

Standard HT protocols (3–5 sessions, 5–6 leeches/session) do not produce clinically significant anemia in adult patients
Daily/extended applications in surgical settings carry higher risk, especially in children and neonates — CBC monitoring mandatory
Hemoglobin recovery occurs during treatment with adequate inter-session intervals
ESR reduction may represent secondary benefit mediated by cholesterol reduction
Transient leukocytosis (peaking 16–18 hours) followed by lymphocyte-mediated leukopenia (resolving by 24–30 hours) = physiological, not pathological

Recommended Hematologic Monitoring

Parameter	When to Obtain	Clinical Threshold
CBC with differential	Baseline, after 3rd session, end of course	Hgb drop >2 g/dL: evaluate for continued HT
Reticulocyte count	If Hgb drops >1 g/dL	Assess bone marrow response
Platelet count	Baseline, mid-course	Drop >30% from baseline: evaluate
ESR	Baseline, end of course	Document response; expect reduction

Coagulation Parameters

Bidirectional Hemostasis Correction (Isakhanyan Model)

One of the most distinctive findings in hirudotherapy research is the corrective model: leech therapy restores hemostatic balance bidirectionally — parameters that are pathologically elevated decrease, while those that are pathologically depressed increase, both moving toward physiologic norms. This distinguishes HT from conventional anticoagulants, which uniformly shift coagulation in one direction.

Parameter	Direction	Change	P
Prothrombin Index	Normalized ↓	96.87 → 76.81	<0.001
Fibrinogen (elevated)	↓ toward normal	Above-normal decreases	<0.01
Fibrinogen (depressed)	↑ toward normal	Below-normal increases	<0.01
Blood Fibrinolytic Activity	Bidirectional	Corrected in both directions	Significant
TEG Parameters	Confirmed restoration	Thromboelastography confirmation	Consistent

Mechanism: The multi-target SGS — simultaneously inhibiting thrombin (hirudin), factor Xa (antistasin), platelet adhesion (calin), and providing thrombolytic activity (destabilase) while not having general proteolytic activity — explains the bidirectional correction. Conventional anticoagulants target a single pathway; SGS modulates the entire hemostatic balance.

Recommended Coagulation Monitoring

Parameter	When to Obtain	Notes
APTT	Baseline, mid-course	May prolong 1.5–2× during active HT; expect restoration 24–48h post-session
PT / INR	Baseline; before each session if on warfarin	Hold HT if INR >3.0
Fibrinogen	Baseline, end of course	Document bidirectional correction pattern
D-dimer	If DVT/PE suspected	May be transiently elevated post-HT due to destabilase-mediated fibrin lysis
Bleeding time	Baseline if concern	Prolonged during active HT (expected pharmacological effect)

Protein & Bilirubin Metabolism

HT from reflex hepatic zones produces measurable improvements in hepatic synthetic and conjugation function, with controlled study data supporting these effects.

Hepatic Function After Single Application (Isakhanian, 1991)

5 ML to right hypochondrium; measured before and after leech detachment

Parameter (Normal Range)	n	Baseline (M ± m)	After ML Detachment	P
Total bilirubin (2–20 µmol/L)	10	28.56 ± 1.28	23.42 ± 1.82	<0.05
Conjugated bilirubin (0–5 µmol/L)	15	7.40 ± 0.50	6.69 ± 0.74	<0.02
Thymol turbidity (0–5 units)	24	2.43 ± 0.27	3.33 ± 0.25	<0.02
Sublimate turbidity (1.6–2.2 mL)	15	1.87 ± 0.05	1.82 ± 0.05	>0.1

The reduction of elevated bilirubin indicates beneficial effects on hepatic conjugation function, attributable to improved hepatic blood flow, venous decompression, and reduced congestion.

Protein Metabolism

In 25 patients with heart/pulmonary failure, serum total protein after single 5-ML application to right hypochondrium showed a tendency to increase (globulin fraction) — not statistically significant (p>0.1). Albumin reduction was also non-significant. However, Dong, Chen, and Tang (1995) reported marked proteinuria reduction and significant serum albumin increase in glomerulonephritis patients — suggesting that the protein-modifying effect may be more pronounced in renal disease.

Ceruloplasmin — Controlled Study (Nazaryan, 2001)

Ceruloplasmin is a hepatically synthesized protein that serves as a principal endogenous antioxidant and hemorheology modulator (reduces platelet adhesion). In CHF, reduced hepatic synthesis leads to decreased ceruloplasmin, increased lipid peroxidation, and worsened hemorheology.

Group	n	Baseline	After Treatment	P
HT + pharmacotherapy	16	20.1 ± 2.7 mg%	27.2 ± 1.25 mg%	<0.05
Pharmacotherapy alone (control)	8	Low	No significant change	>0.05

CHF stage IIb patients. HT from reflex hepatic zones restored ceruloplasmin to normal values — a statistically significant improvement absent in the control group.

Hepatic Detoxification — Controlled Study

In CHF, reduced cardiac output and increased right atrial pressure propagate to the hepatic veins and portal system, leading to venous congestion, hypoxia, and hepatocyte necrosis. The liver, lungs, and kidneys are converted from filters that neutralize endotoxins into sources that generate them (Nazaryan, 1999).

Nazaryan (2001) — Endotoxin Clearance Study

Parameter	HT Group (n=16)	Control (n=10)
Population	CHF stage IIb, elevated endotoxins	CHF stage IIb, elevated endotoxins
Intervention	Pharmacotherapy + HT from hepatic/pulmonary reflex zones	Pharmacotherapy alone
Measurement	UV spectrophotometry of deproteinized supernatant (cubital venous blood), before and 5 days post-course
Endotoxin decrease	12/16 patients (75%) — p<0.05	4/10 patients (40%) — p>0.05
Medication dose reduction	14/16 (87.5%) could substantially reduce nitrates, glycosides, ACE-I	Not reported

Dual-Action Mechanism

The proposed mechanism involves two simultaneous pathways:

Mechanical removal: Extraction of endotoxin-saturated blood and lymph from the hepatic lymphatic and blood circulation
Pharmacological delivery: Introduction of the full complement of biologically active SGS compounds — anti-inflammatory (eglins), anti-thrombotic (hirudin), and tissue-remodeling (hyaluronidase)

This dual action produces more effective restoration of detoxifying function than either pharmacotherapy or bloodletting alone.

Restored Pharmacotherapy Sensitivity

In 14 of 16 HT patients (87.5%), maintenance doses of nitrates, cardiac glycosides, and ACE inhibitors could be substantially reduced — indicating restored pharmacotherapy sensitivity. The mechanism: HT breaks the pathological cycle of endogenous intoxication, restoring albumin synthesis and utilization (albumins serve the transport function for drug molecules).

Clinical implication: Medication dose adjustments may be necessary in CHF patients undergoing HT to prevent overtreatment as organ function improves. Monitor for signs of medication excess (hypotension, bradycardia) and reduce doses accordingly.

Gas Discharge Visualization (GDV) Monitoring

Gas discharge visualization, based on the Kirlian effect, involves observation of gas discharge luminescence in a high-intensity electric field. Krashenyuk, Korotkov, and colleagues (1997–2003) applied this method to monitor HT effects.

Response Classification

Type	Definition	Frequency
Superergic	Luminescence area increase >10%	14%
Hyperergic	Increase 5.1–10%	15%
Normoergic	Increase 1–5%	39%
Hypoergic	Increase <1% or decrease	32%

Protocol: measurements before session, immediately after, and 30 minutes post-detachment. Uses “Corona TV” system for quantitative tracking.

Critical Assessment

While GDV has produced consistent classification data and Korotkov (1999) demonstrated it reveals parameters related to functional state and localized electrochemical skin phenomena, this method has not gained acceptance in mainstream clinical practice. It requires extensive validation against established clinical endpoints before recommendation for routine monitoring. Its primary value at present lies in research applications exploring the biophysical dimension of HT effects.

GRADE Evidence Level: Very Low

Case reports, case series, or expert opinion only

Comprehensive Monitoring Panel

Based on the published evidence, the following integrated monitoring panel is recommended for systematic documentation of hirudotherapy effects and patient safety.

Domain	Parameters	Timing	Clinical Significance
Hematology	CBC with differential, reticulocytes (if needed)	Baseline, mid-course, end; daily for surgical	Anemia detection; leukocyte response documentation; platelet safety
Lipids	TC, TG, LDL-C, HDL-C, non-HDL-C	Baseline, 4 weeks, 12 weeks	Metabolic response; sustained improvements at 90 days
Coagulation	APTT, PT/INR, fibrinogen	Baseline, during therapy; each session if on anticoagulants	Bidirectional correction; safety in anticoagulated patients
Hepatic	ALT, AST, total/direct bilirubin, albumin, GGT	Baseline, end of course	Synthetic function; conjugation capacity; hepatoprotective response
Antioxidant	Ceruloplasmin	Baseline, end of course (if CHF)	Antioxidant capacity; hemorheology modulation
Inflammatory	ESR, CRP	Baseline, end of course	Document anti-inflammatory response; ESR reduction expected

Hepatic Function Panel (for hepatic applications)

Parameter	When to Obtain	Clinical Significance
AST / ALT	Baseline, end of course	Hepatocellular integrity
Total / direct bilirubin	Baseline, post-session, end of course	Hepatic conjugation capacity
Albumin	Baseline, end of course	Synthetic function; drug transport capacity
GGT	Baseline, end of course	Cholestatic assessment
INR	Baseline, mid-course	Synthetic function (coagulation factor production)

Safety Thresholds

Hgb <8 g/dL

Absolute Contraindication

Do not initiate or continue leech therapy. Hemoglobin below 8 g/dL indicates insufficient oxygen-carrying capacity to tolerate additional blood loss. Transfuse and reassess.

Platelets <100K

Hold Therapy

Thrombocytopenia below 100,000/µL increases bleeding risk from bite sites. Hold therapy until count recovers. Note: Isakhanian (1991) confirmed that single ML application does NOT alter platelet count in patients with normal baseline (259 ± 8/µL, unchanged).

INR >3.0

Hold Anticoagulation

Supratherapeutic anticoagulation must be corrected before proceeding. Hold warfarin or DOAC, recheck INR in 24–48 hours. Coordinate with prescribing physician for dose adjustment. Note: The bidirectional correction model suggests HT may help restore coagulation balance, but this should not be relied upon in supratherapeutic ranges.

Hgb Drop >2 g/dL

Evaluate Continuation

A hemoglobin drop exceeding 2 g/dL from baseline during a treatment course warrants evaluation. Check reticulocyte count to assess bone marrow response. Consider extending inter-session intervals, reducing leech count per session, or discontinuing therapy if recovery is inadequate.

Platelet Drop >30%

Evaluate Etiology

Platelet reduction exceeding 30% from baseline requires investigation. Startseva et al. (2001) documented moderate platelet reduction (p<0.05) with intravaginal application that normalized before the next course. Rule out HIT (heparin-induced thrombocytopenia) if concurrent heparin use, and other consumptive causes.

Key Takeaways

Lipid metabolism: HT significantly reduces TC and TG (9 studies); reductions in LDL and increases in HDL are documented at 90-day follow-up, consistent with SGS lipase/cholesterol esterase activity
Anemia risk: Standard protocols do not produce clinically significant anemia in adults; daily surgical protocols require close monitoring (49.75% transfusion rate in microsurgical salvage)
Hepatic function: HT from hepatic reflex zones significantly increases ceruloplasmin (p<0.05), reduces bilirubin (p<0.05), and decreases endotoxins (75% vs 40% in controls)
Pharmacotherapy sensitivity: 87.5% of CHF patients could reduce medication doses after HT-mediated detoxification — monitor for overtreatment as organ function improves
Bidirectional correction: Unlike conventional anticoagulants, HT restores hemostatic parameters in both directions — a unique property attributable to multi-target SGS activity
Systematic monitoring: Lipid panel, CBC, coagulation, and hepatic function tests should be incorporated into all HT treatment protocols to document response and guide dosing

Key Laboratory Studies

Published studies documenting laboratory parameter changes during hirudotherapy
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Isakhanian GS 1991	Prospective observational	Patients with hepatic region application (n=20)	Single application of 5 leeches to hepatic region	Lipid metabolism parameters	TC decreased from 4.69 to 3.99 mmol/L (p<0.05); TG from 1.29 to 0.89 mmol/L (p<0.05) after single application. Ter Arkh
Kovalenko VN et al. 1998	Prospective observational	CAD patients (n=43)	Hirudotherapy course with 90-day follow-up	Lipid profile at 90 days	Significant reductions in TC (p<0.05), TG (p<0.05), LDL (p<0.01); significant increase in HDL-C (p<0.05). Kardiologiya
Zadorova GP 1998	Prospective observational	CAD and hypertension patients (n=NR)	Hirudotherapy course	Lipid improvement rates	TC returned to reference range in 57%; LDL decreased in 52%; atherogenic index decreased in 50% of cases. Ros Kardiol Zh
Dong, Chen, Tang 1995	Prospective observational	Primary glomerulonephritis patients (n=31)	Hirudotherapy course	Lipid and renal parameters	Significant improvement in TC and TG levels; proteinuria reduction; serum albumin increase. Chin J Nephrol
Eldor A et al. 1998	Prospective observational	Post-phlebitic syndrome patients (n=NR)	Extended hirudotherapy (>20 sessions)	Hemoglobin stability	No decline in hemoglobin even in patients receiving >20 hirudotherapy sessions. Br J Haematol
Lukina IS & Korletyanu EV 1999	Prospective observational	Human subjects and rat model (n=NR)	Hirudotherapy course	Hematologic parameters	Humans: no red cell changes; ESR significantly slowed (p<0.05). Relative increase in segmented neutrophils (p<0.05), decrease in lymphocytes. No eosinophilia. Gematol Transfuziol
Startseva NV et al. 2001	Prospective observational	Endometriosis patients (intravaginal application) (n=NR)	Intravaginal hirudotherapy	RBC, Hgb, platelet changes	Significant decrease in RBC/Hgb after 1–2 sessions (recovered by end of course); moderate platelet reduction (p<0.05) normalized before next course. Akush Ginekol
Nazaryan RS 2001	Non-randomized controlled	CHF patients (HT n=16 vs control n=10) (n=26)	Hirudotherapy vs standard care	Ceruloplasmin and endotoxin levels	HT group: ceruloplasmin 20.1→27.2 mg% (p<0.05); endotoxins decreased in 75% (p<0.05). Control: 40% response (NS). 14/16 HT patients could reduce medication doses. Kardiologiya
Isakhanian GS 1991	Prospective observational	Patients with right hypochondrium application (n=24)	Single application of leeches to hepatic region	Hepatic function parameters	Total bilirubin 28.56→23.42 µmol/L (p<0.05); conjugated bilirubin 7.40→6.69 µmol/L (p<0.02); thymol turbidity 2.43→3.33 (p<0.02). Ter Arkh
Krashenyuk AI et al. 2003	Prospective observational	Hirudotherapy patients (GDV monitoring) (n=NR)	Gas discharge visualization before/after treatment	Bioenergetic response classification	Classified 4 response types by luminescence area: superergic (14%), hyperergic (15%), normoergic (39%), hypoergic (32%). Proc Int Conf Biol Ther

Evidence Gaps & Research Priorities

Methodological Limitations

Most studies are observational (Level III–IV); no RCTs for lipid or hepatic endpoints
Sample sizes are small (n=8–43); larger studies needed
Many studies report incomplete numerical data (“NR” for sample sizes)
Follow-up is limited; only Kovalenko (1998) reports 90-day data
Confounding variables (concurrent medications, diet, exercise) poorly controlled

Research Priorities

Prospective RCTs for lipid-modifying effects with standardized endpoints
Larger controlled studies of hepatic detoxification in CHF
Validation of the bidirectional hemostasis correction model with modern viscoelastic testing (TEG, ROTEM)
Standardized laboratory monitoring protocols for clinical practice guidelines
Long-term follow-up (>12 months) for sustained metabolic effects